Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582775 · ClinicalTrials.gov registry record · Phase 2
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02582775 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 17 participants.
The verdict
NCT02582775, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of severe epidermolysis bullosa (EB).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Thymoglobulin
- RADIATION Total Body Irradiation
- PROCEDURE Bone marrow infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-03 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582775
The ClinicalTrials.gov registry entry for NCT02582775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02582775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02582775 about?
NCT02582775 is a clinical study titled "MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs". This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of seve...
What is the current status of trial NCT02582775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2016-03. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT02582775?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Thymoglobulin (DRUG), Total Body Irradiation (RADIATION), Bone marrow infusion (PROCEDURE).
Who is sponsoring clinical trial NCT02582775?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.